Results from the TRILUMINATE study, presented this week at EuroPCR 2019 in Paris, suggest Abbott’s minimally invasive tricuspid valve repair system is an effective solution for patients with structural heart disease, reducing the severity of tricuspid regurgitation (TR) in more than 85% of test cases.

Catheter-directed therapy (CDT) is being used to treat pulmonary embolism (PE) more and more by healthcare providers, according to new research published in the Journal of Vascular and Interventional Radiology.

The Pascal transcatheter mitral valve repair (TMVR) system has received its CE mark for the treatment of patients with mitral regurgitation, device manufacturer Edwards Lifesciences announced Feb. 19.

The Society for Cardiovascular Angiography and Interventions (SCAI) weighed in on the ongoing debate regarding the long-term safety of paclitaxel-coated balloons and stents on Jan. 25, largely agreeing with the FDA’s stance that the benefits of such devices appear to outweigh the risks until more information becomes available.

LEIPZIG and MARLBOROUGH, Mass. (January 22, 2019) — Boston Scientific (NYSE: BSX) today announced diabetic subanalysis results from the IMPERIAL trial in which patients treated with the ELUVIA™ Drug-Eluting Vascular Stent System demonstrated statistically significant lower rates of target lesion revascularization (TLR) and stent thrombosis when compared to those treated with the Zilver® PTX® Drug-Eluting Peripheral Stent. 

Abbott plans to acquire Cephea Valve Technologies, a company developing a transcatheter mitral valve replacement (TMVR) device, the Chicago-area healthcare giant announced Jan. 16.

For-profit and not-for-profit healthcare facilities may value the health of their cath lab employees differently. Without a clear indication of the bottom-line impact, some hospitals may be forgoing protective equipment and sacrificing the long-term health of their workers. Should the C-suite prioritize worker health when allocating investment dollars? 

Will operators be able to replicate COAPT’s restraint and its outcomes?